Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Inclusion Criteria:

* metastatic adenocarcinoma of the colon or rectum
* wild-type KRAS tumor status
* radiographic evidence of disease progression during or following treatment with irinotecan and/or oxaliplatin containing chemotherapy for mCRC
* measurable disease \>/= 20 mm per Response Evaluation Criteria In Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* adequate laboratory values

Exclusion Criteria:

* history of central nervous system (CNS) metastases
* history of another primary cancer, unless:
* curatively resected non-melanomatous skin cancer
* curatively treated cervical carcinoma in situ
* other primary solid tumor treated with curative intent and no known active disease present for \>/= 5 years
* prior treatment with an anti-epithelial growth factor receptor (EGFR), hepatocyte growth factor receptor (HGFR, c-MET), and/or insulin-like growth factor receptor (IGFR) inhibitor
* prior treatment with AMG 102 or AMG 479
* prior treatment with chemotherapy or radiotherapy \</= 21 days
* prior treatment with targeted therapy \</= 30 days
* known allergy or hypersensitivity to panitumumab, AMG 102, or AMG 479
* history of interstitial lung disease
* clinically significant cardiovascular disease \</= 1 year
* active inflammatory bowel disease
* known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B infection
* any co-morbid disease or condition that could increase the risk of toxicity
* serious or non-healing wound \</= 35 days
* any uncontrolled concurrent illness or history of any medical condition that could interfere with the interpretation of the study results
* major surgical procedure \</= 35 days or minor surgical procedure \</= 14 days
* other investigational procedures or drugs \</= 30 days